Aplastic anemia (AA), a rare autoimmune disorder, is caused by insufficient production of red blood cells, white blood cells, and platelets due to bone marrow failure. Its prevalence is higher in Asia, affecting 4.5 individuals per million under the age of 15, with rates 2-3 times greater than in Western countries. The exact cause remains unknown, but cytotoxic T cells attacking self-hematopoietic stem cells and bone marrow precursors trigger the condition. The standard treatment, utilizing immunosuppressive drugs like ATG, exhibits a 60-70% efficacy. However, prolonged use may result in drug resistance and complications. In severe cases, hematopoietic stem cell transplantation is considered, but the associated mortality risk (around 10%) underscores the urgent need for innovative therapies.
Immunique's regulatory T cell therapy (IMQ101-AA) aims to mitigate the hyperactive immune response caused by cytotoxic T cells in aplastic anemia patients. This approach not only enhances therapeutic efficacy but also minimizes potential side effects, representing a promising treatment option.
